(Q33560391)

28 July 2017

1 reference

title

Ondansetron: a pharmacoeconomic and quality-of-life evaluation of its antiemetic activity in patients receiving cancer chemotherapy (English)

1 reference

28 July 2017

1 reference

1 reference

Plosker GL

1

1 reference

28 July 2017

Milne RJ

series ordinal

2

1 reference

28 July 2017

publication date

1 October 1992

1 reference

28 July 2017

1 reference

28 July 2017

volume

2

1 reference

28 July 2017

issue

4

1 reference

28 July 2017

page(s)

285-304

1 reference

An overview on the use of granisetron in the treatment of emesis associated with cytostatic chemotherapy

28 July 2017

cites work

1 reference

12 December 2020

Extrapyramidal reactions with high-dose metoclopramide

1 reference

12 December 2020

Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis. Italian Group For Antiemetic Research

1 reference

12 December 2020

Ondansetron versus metoclopramide in the prevention of chemotherapy-induced nausea and vomiting - a metaanalysis

1 reference

12 December 2020

Extrapyramidal reaction to ondansetron

1 reference

12 December 2020

Publication of unethical studies on the treatment of chemotherapy-induced emesis

1 reference

12 December 2020

Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens

1 reference

12 December 2020

Ondansetron plus dexamethasone: an effective combination in high-dose cisplatin therapy. The Italian Oncology Group for Clinical Research

1 reference

12 December 2020

Ondansetron. Therapeutic use as an antiemetic

1 reference

12 December 2020

Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone

1 reference

12 December 2020

Ondansetron versus dexamethasone

1 reference

12 December 2020

Pharmacological characterization of 5-hydroxytryptamine-induced depolarization of the rat isolated vagus nerve

1 reference

12 December 2020

Consensus meeting agrees distribution of 5-HT3 receptors in mammalian hindbrain

1 reference

12 December 2020

The role of ondansetron in the treatment of emesis induced by non-cisplatin-containing chemotherapy regimes.

1 reference

12 December 2020

Reduction of carboplatin induced emesis by ondansetron

1 reference

12 December 2020

Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study. Ondansetr

1 reference

12 December 2020

5-HT3 receptor binding sites are on capsaicin-sensitive fibres in the rat spinal cord.

1 reference

12 December 2020

5-HT3 receptor antagonists injected into the area postrema inhibit cisplatin-induced emesis in the ferret

1 reference

12 December 2020

Efficacy of Ondansetron (Gr 38032F) and the Role of Serotonin in Cisplatin-Induced Nausea and Vomiting

1 reference

12 December 2020

Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy

1 reference

12 December 2020

Oral treatment with ondansetron in an outpatient setting

1 reference

12 December 2020

The role of the abdominal visceral innervation and 5-hydroxytryptamine M-receptors in vomiting induced by the cytotoxic drugs cyclophosphamide and cis-platin in the ferret

1 reference

12 December 2020

Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer

1 reference

12 December 2020

Effective emetic control during conditioning of children for bone marrow transplantation using ondansetron, a 5-HT3 antagonist

1 reference

12 December 2020

Ondansetron and cisplatin-induced nausea and vomiting

1 reference

12 December 2020

Pharmacoeconomics of intravenous drug administration

1 reference

12 December 2020

5-HT3 antagonist ondansetron--an effective outpatient antiemetic in cancer treatment

1 reference

12 December 2020

A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: a randomized, double-blind study. International Emesis Study Group.

1 reference

12 December 2020

Safety of ondansetron

1 reference

12 December 2020

1 reference

12 December 2020

The role of specific 5-HT3 receptor antagonism in the control of cytostatic drug-induced emesis.

1 reference

12 December 2020

Progress in the control of acute and delayed emesis induced by cisplatin

1 reference

12 December 2020

Advances in the management of cytotoxic drug-induced nausea and vomiting

1 reference

12 December 2020

Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron?

1 reference

12 December 2020

Ondansetron (GR38032F) plus dexamethasone: effective anti-emetic prophylaxis for patients receiving cytotoxic chemotherapy

1 reference

12 December 2020

Protection from nausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and diphenhydramine: a study of the Italian Oncology Group for Clinical Re

1 reference

12 December 2020

A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy

1 reference

12 December 2020

Low dose ondansetron and dexamethasone: a cost effective alternative to high dose metoclopramide/dexamethasone/lorazepam in the prevention of acute cisplatin induced emesis

1 reference

12 December 2020

Ondansetron as an antiemetic

1 reference

12 December 2020

The 5-HT3 receptor ligand, [3H]BRL 43694, binds to presynaptic sites in the nucleus tractus solitarius of the rat

1 reference

12 December 2020

On the receiving end--patient perception of the side-effects of cancer chemotherapy.

1 reference

12 December 2020

Prevention of cyclophosphamide/cytarabine-induced emesis with ondansetron in children with leukemia

1 reference

12 December 2020

Principles of pharmacoeconomic analysis of drug therapy

1 reference

12 December 2020

Anticipatory vomiting in women receiving cyclophosphamide, methotrexate, and 5-FU (CMF) adjuvant chemotherapy for breast carcinoma

1 reference

12 December 2020

Neuropharmacology of emesis induced by anti-cancer therapy.

1 reference

12 December 2020

Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism

1 reference

12 December 2020

Evidence for presynaptic 5-hydroxytryptamine3 recognition sites on vagal afferent terminals in the brainstem of the ferret

1 reference

12 December 2020

Measurement of quality of life in clinical trials

1 reference

12 December 2020

Cisplatin induced emesis: preliminary results indicative of changes in plasma levels of 5-hydroxytryptamine

1 reference

12 December 2020

Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy

1 reference

12 December 2020

Antagonism of the effects of 5-hydroxytryptamine on the rabbit isolated vagus nerve by BRL 43694 and metoclopramide

1 reference

12 December 2020

The abdominal visceral innervation and the emetic reflex: pathways, pharmacology, and plasticity

1 reference

12 December 2020

Assessing quality of life in cancer patients

1 reference

12 December 2020

A primer on geriatric psychopharmacology

1 reference

12 December 2020

Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting

1 reference

12 December 2020

Is ondansetron "too expensive"?

1 reference

12 December 2020

Double-blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide

1 reference

12 December 2020

The symptomatic control of cytostatic drug-induced emesis. A recent history and review

1 reference

12 December 2020

Economic evaluation of ondansetron: preliminary analysis using clinical trial data prior to price setting

1 reference

12 December 2020

Optimum management of nausea and vomiting in cancer chemotherapy

1 reference

12 December 2020

A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy

1 reference

12 December 2020

The antiemetic efficacy and the cost-benefit ratio of ondansetron calculated with a new approach to health technology assessment (real cost-benefit index)

1 reference

12 December 2020

ONDANSETRON WITH AND WITHOUT DEXAMETHASONE TO TREAT CHEMOTHERAPY-INDUCED EMESIS

1 reference

12 December 2020

[Ondansetron (GR 38032F), a competitive 5-HT3 receptor antagonist as an antiemetic in cytostatic drug-induced nausea and vomiting. An open, substance-oriented phase II/III study]

1 reference

12 December 2020

Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis.

1 reference

12 December 2020

Parenteral ondansetron for the treatment of chemotherapy- and radiation-induced nausea and vomiting

1 reference

12 December 2020

Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study.

1 reference

12 December 2020

Is ondansetron a less effective antiemetic against moderately emetic as compared with highly emetic chemotherapy?

1 reference

12 December 2020

Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Results of consecutive trials in 255 patients.

1 reference

12 December 2020

10.2165/00019053-199202040-00005

Identifiers

DOI

1 reference

Dimensions Publication ID

28 July 2017

1005768944

0 references

1 reference